News

Cortex’s CEO To Present At The Roth Capital Partners 19th Annual Orange County Conference

IRVINE, Calif., (February 13, 2007) — Cortex Pharmaceuticals, Inc. (AMEX: COR), Chairman, President and CEO, Roger G. Stoll, Ph.D., will speak at the 19th Annual Roth Capital Partners Growth Stock Conference to be held at The Ritz-Carlton Laquna Nigel Hotel located in Dana Point, California. Dr Stoll will speak at 5:00 pm PST (8:00 pm EST) in the Ritz Ballroom – Salon 2 on February 21, 2007. The conference will feature over 300 small-cap companies across a broad spectrum of sectors, including technology, healthcare, financial services and consumer products.

Dr. Stoll will provide a comprehensive update on Cortex’s 2007 Corporate objectives and milestones, including an update on the progress with it lead low impact AMPAKINE® product candidate, CX717, as a novel ADHD treatment, as well as on other scientific and corporate developments. A live webcast of the presentation can be accessed by logging onto http://www.wsw.com/webcast/roth9/cor/ A replay will be available for 30 days following the conference.

More information regarding the conference can be found at http://www.rothconference.com/

About Cortex
Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. The Company is pioneering a class of proprietary pharmaceuticals called Ampakine® compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer’s disease. Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain’s neurotransmitter system. These imbalances may be improved by using the Ampakine technology. Cortex has alliances with N.V. Organon for the treatment of schizophrenia and depression and with Les Laboratoires Servier for the development of Ampakine compounds to treat the neurodegenerative effects associated with aging and disease, including Mild Cognitive Impairment, Alzheimer’s disease and anxiety disorders. For additional information regarding Cortex, please visit Cortex Pharmaceuticals’ Website at www.cortexpharm.com

Contacts:

Roger G. Stoll, Ph.D.
Chairman, President and CEO
Cortex Pharmaceuticals, Inc.
(949) 727-3157

Erika Moran/Dian Griesel, Ph.D.
Media Contact: Janet Vasquez/
Lynn Granito
The Investor Relations Group
(212) 825-3210